Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
The European guideline for thymoma and thymic carcinoma, built on the French RYTHMIC network's experience: complete surgery where possible, radiotherapy for invasive tumours and platinum chemotherapy for disease that cannot be removed.
Overview
ESMO guideline covering the diagnosis, WHO histological typing, Masaoka-Koga and TNM staging, surgery, postoperative radiotherapy, induction chemotherapy for locally advanced tumours, chemotherapy and targeted agents for advanced disease, and follow-up of thymic epithelial tumours, with treatment recommended through multidisciplinary tumour boards such as RYTHMIC.
It recommends complete resection as the cornerstone, postoperative radiotherapy for stage III and incompletely resected tumours and for thymic carcinoma, cisplatin-based combinations for unresectable disease, and lists octreotide, sunitinib and everolimus as options after chemotherapy.
The thymoma and thymic carcinoma pages follow this guideline for who gets surgery, radiotherapy and chemotherapy; its central message is that these rare tumours should be discussed in an expert network.
- Most recommendations rest on retrospective series; no randomised trial has compared surgery with or without radiotherapy.
- Predates the lenvatinib and pembrolizumab studies in thymic carcinoma.
Similar pages
not linked directly; found by shared links- Key paperThe 2021 WHO classification of tumours of the thymus and mediastinum: what is new in thymic epithelial, germ cell and mesenchymal tumours
Shares Thymoma (WHO types A, AB, B1, B2 and B3), Thymic carcinoma.
- TreatmentEB-CAR30-NK
Shares Thymoma (WHO types A, AB, B1, B2 and B3), Thymic carcinoma.
- TrialA Study of KC1036 in Patients with Advanced Thymic Tumors
Shares Thymoma (WHO types A, AB, B1, B2 and B3), Thymic carcinoma.
- TrialTarget-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma
Shares Thymoma (WHO types A, AB, B1, B2 and B3), Thymic carcinoma.
- Key paperASPEN: everolimus versus sunitinib in metastatic non-clear cell renal cell carcinoma
Shares Sunitinib, Everolimus.
- TrialCLEAR (KEYNOTE-581)
Shares Sunitinib, Everolimus.
- CancerThymoma and thymic carcinoma
Shares Thymoma (WHO types A, AB, B1, B2 and B3), Thymic carcinoma, Sunitinib, Everolimus.
- TreatmentKC1036
Shares Thymoma (WHO types A, AB, B1, B2 and B3), Thymic carcinoma.